论文信息 - Brain amyloid imaging--FDA approval of florbetapir F18 injection.

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

The FDA has approved a new radiopharmaceutical agent to assist in detecting causes of cognitive impairment other than Alzheimer's disease. But unique features of imaging information obtained with florbetapir F18 injection require careful consideration in diagnosis.

Lucie Yang | D. Rieves | C. Ganley

[1] S. Okie. Confronting Alzheimer's disease. , 2011, The New England journal of medicine.

[2] Tyler E. Benedum,et al. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. , 2011, Seminars in nuclear medicine.